Talphera (TLPH) Q3 2026 Earnings Call Transcript

Talphera (TLPH) reported Q3 2026 earnings, seeking FDA approval to conclude Niyad enrollment early due to 80% statistical power. They increased peak U.S. sales estimate to over $200M. Cash balance was $14.2M, with $16M in potential financing. Operating expenses rose to $3.8M from $3.3M YoY. Enrollment challenges were discussed, with no clear cause identified.

Original reporting
Published Nov 13, 2026, 6:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Talphera (TLPH) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$TLPHBullishMed
01

Why it matters

The company seeks FDA Sprint Meeting feedback and projects >$200M peak U.S. sales, indicating a sizable market opportunity.

02

Market read

New guidance on cash, expenses, and market potential could move TLPH stock as investors reassess valuation.

03

What to watch

Regulatory timeline uncertainty and competitive landscape in CRRT anticoagulation.

Relevance 7/10Novelty 6/10Timing: today

Background

Talphera is a medical‑device company developing Niyad, a nafamostat‑based anticoagulant for CRRT.

Company-level read

Ticker impact

$TLPHBullishHigh confidence
Context

Q3 2026 earnings call disclosed cash balance of $14.2M, increased R&D expenses, and a $200M peak sales estimate for Niyad.

Expected impact

potential modest upside as investors price in stronger commercial potential and sufficient cash runway

Evidence & confidence

The call provides fresh guidance on sales potential and cash resources, which were not previously public.

Market effects

Highlights growth prospects for CRRT anticoagulation market and may benefit peer medical device firms.

U.S. market focus with potential FDA feedback later this year.

Limited to niche medical device sector; no broad macro impact.

Counterpoint

If enrollment delays persist, the sales outlook may be overly optimistic.

Key entities

  • Talphera

    Developer of Niyad, subject of the earnings call.

  • FDA

    Target of Sprint Meeting request for Niyad's regulatory pathway.

Related articles

$TLPHMed

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

$TLPHMedAI 8/10

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

$TLPHMed

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi